Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Amortization of Deferred Charges: 2019-2024

Historic Amortization of Deferred Charges for Gossamer Bio (GOSS) over the last 6 years, with Dec 2024 value amounting to $1.1 million.

  • Gossamer Bio's Amortization of Deferred Charges rose 5.98% to $248,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $972,000, marking a year-over-year decrease of 15.92%. This contributed to the annual value of $1.1 million for FY2024, which is 17.79% down from last year.
  • According to the latest figures from FY2024, Gossamer Bio's Amortization of Deferred Charges is $1.1 million, which was down 17.79% from $1.3 million recorded in FY2023.
  • Gossamer Bio's Amortization of Deferred Charges' 5-year high stood at $6.7 million during FY2021, with a 5-year trough of $1.1 million in FY2024.
  • Its 3-year average for Amortization of Deferred Charges is $1.2 million, with a median of $1.2 million in 2022.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 1,527.43% in 2020, then slumped by 82.72% in 2022.
  • Gossamer Bio's Amortization of Deferred Charges (Yearly) stood at $3.9 million in 2020, then skyrocketed by 74.51% to $6.7 million in 2021, then crashed by 82.72% to $1.2 million in 2022, then grew by 13.59% to $1.3 million in 2023, then fell by 17.79% to $1.1 million in 2024.